Syntekabio said that it will develop immunotherapy agents jointly with CHA Hospital by using the company’s artificial intelligence (AI) platform Deep Matcher.
The two institutions will research developing a combination therapy for immune gateway inhibitors. The agreement came after the two parties signed a contract to co-develop STB001, an immunotherapy agent developed using Syntekabio’s AI drug discovery platform.
“We will establish and carry out a research strategy to maximize the therapeutic effect of the candidate,” the company said. “Also, we will collaborate on new drug development, including immunotherapy, using genome big data and AI models.”
CHA Hospital is an international medical organization that operates 61 hospitals in seven countries, including the CHA Bundang Hospital, CHA Gangnam Medical Center, CHA GUMI Medical Center, in Korea, and other hospitals in the U.S., Australia, and Singapore.
Professors Jeon Hong-jae and Kim Chan, a leading cancer researcher at CHA Bundang Hospital, are experts in the field of immunotherapy drugs. He is actively conducting academic consultations and early clinical trials for developing new anticancer drugs.
They have developed and published new immunotherapeutic methods using STING and anticancer viruses in prominent international journals, and are actively conducting academic advisory and initial clinical trials for the development of new global anticancer drugs.
Syntekabio is discovering new drug candidates using genome big data and AI, developing biomarkers to increase clinical trial success rates, and providing genome precision medical services.
<© Korea Biomedical Review, All rights reserved.>